A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease

BMC Cancer

Punit Kaur⁵  Ganachari M Nagaraja⁵  Hongying Zheng⁵  Dawit Gizachew³  Moses Galukande²  Sunil Krishnan¹  Alexzander Asea⁴ 

[1] Department of Radiation Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA

[2] Department of Surgery, Makerere University, P. O. Box 7072, Kampala, Uganda

[3] Department of Medicine, Scott & White Memorial Hospital and Clinic and the Texas A&M Health Science Center, College of Medicine, Temple, TX 76508, USA

[4] Division of Investigative Pathology, Scott & White Memorial Hospital and Clinic and The Texas A&M Health Science Center College of Medicine, 1901 South 1st Street, Building 205, Temple, TX 76504, USA

[5] Department of Pathology, Scott & White Memorial Hospital and Clinic and the Texas A&M Health Science Center, College of Medicine, Temple, TX 76504, USA

关键词: Tumor-initiating cells;    Cancer stem cells;    Heat shock;    Hsp72/HspA1A;    Hsp27;    Hsp25;    Mouse and human HspB1;    Triple-negative breast cancer;   

Others  :  1080487
DOI  :  10.1186/1471-2407-12-120

 received in 2011-09-11, accepted in 2012-03-27,  发布年份 2012

【 摘 要 】

Background

Triple-negative breast cancer (TNBC) exhibit characteristics quite distinct from other kinds of breast cancer, presenting as an aggressive disease--recurring and metastasizing more often than other kinds of breast cancer, without tumor-specific treatment options and accounts for 15% of all types of breast cancer with higher percentages in premenopausal African-American and Hispanic women. The reason for this aggressive phenotype is currently the focus of intensive research. However, progress is hampered by the lack of suitable TNBC cell model systems.

Methods

To understand the mechanistic basis for the aggressiveness of TNBC, we produced a stable TNBC cell line by sorting for 4T1 cells that do not express the estrogen receptor (ER), progesterone receptor (PgR) or the gene for human epidermal growth factor receptor 2 (HER2). As a control, we produced a stable triple-positive breast cancer (TPBC) cell line by transfecting 4T1 cells with rat HER2, ER and PgR genes and sorted for cells with high expression of ER and PgR by flow cytometry and high expression of the HER2 gene by Western blot analysis.

Results

We isolated tumor-initiating cells (TICs) by sorting for CD24⁺/CD44^high/ALDH1⁺ cells from TNBC (TNBC-TICs) and TPBC (TPBC-TICs) stable cell lines. Limiting dilution transplantation experiments revealed that CD24⁺/CD44^high/ALDH1⁺ cells derived from TNBC (TNBC-TICs) and TPBC (TPBC-TICs) were significantly more effective at repopulating the mammary glands of naïve female BALB/c mice than CD24^-/CD44^-/ALDH1^- cells. Implantation of the TNBC-TICs resulted in significantly larger tumors, which metastasized to the lungs to a significantly greater extent than TNBC, TPBC-TICs, TPBC or parental 4T1 cells. We further demonstrated that the increased aggressiveness of TNBC-TICs correlates with the presence of high levels of mouse twenty-five kDa heat shock protein (Hsp25/mouse HspB1) and seventy-two kDa heat shock protein (Hsp72/HspA1A).

Conclusions

Taken together, we have developed a TNBC-TICs model system based on the 4T1 cells which is a very useful metastasis model with the advantage of being able to be transplanted into immune competent recipients. Our data demonstrates that the TNBC-TICs model system could be a useful tool for studies on the pathogenesis and therapeutic treatment for TNBC.

【 授权许可】

   
2012 Kaur et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Burness ML, Grushko TA, Olopade OI: Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 2010, 16(1):23-32.
• [2]Seal MD, Chia SK: What is the difference between triple-negative and basal breast cancers? Cancer J 2010, 16(1):12-16.
• [3]Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, et al.: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27(8):1168-1176.
• [4]Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15 Pt 1):4429-4434.
• [5]Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM: Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009, 118(1):131-137.
• [6]Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423.
• [7]Christiansen JJ, Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006, 66(17):8319-8326.
• [8]Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7(2):131-142.
• [9]Lee KM, Han W, Kim JB, Shin I, Ko E, Park IA, Lee DS, Oh K, Noh DY: The CD49d+/high subpopulation from isolated human breast sarcoma spheres. Int J Oncol 2012, 40(3):665-672.
• [10]Blackburn JS, Liu S, Langenau DM: Quantifying the frequency of tumor-propagating cells using limiting dilution cell transplantation in syngeneic zebrafish. J Vis Exp: JoVE 2011, 53:2790.
• [11]Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, et al.: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA 2012, 109(8):2778-2783.
• [12]Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001, 414(6859):105-111.
• [13]Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al.: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69(10):4116-4124.
• [14]Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2(3):161-174.
• [15]Soldes OS, Kuick RD, Thompson IA, Hughes SJ, Orringer MB, Iannettoni MD, Hanash SM, Beer DG: Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer 1999, 79(3-4):595-603.
• [16]O'Neill PA, Shaaban AM, West CR, Dodson A, Jarvis C, Moore P, Davies MP, Sibson DR, Foster CS: Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br J Cancer 2004, 90(1):182-188.
• [17]Rust W, Kingsley K, Petnicki T, Padmanabhan S, Carper SW, Plopper GE: Heat shock protein 27 plays two distinct roles in controlling human breast cancer cell migration on laminin-5. Mol Cell Biol Res Commun 1999, 1(3):196-202.
• [18]Ciocca DR, Lo Castro G, Alonio LV, Cobo MF, Lotfi H, Teyssie A: Effect of human papillomavirus infection on estrogen receptor and heat shock protein hsp27 phenotype in human cervix and vagina. Int J Gynecol Pathol 1992, 11(2):113-121.
• [19]Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA: The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993, 53(19):4443-4448.
• [20]Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y: Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 2001, 168(2):173-181.
• [21]Storm FK, Mahvi DM, Gilchrist KW: Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol 1996, 3(6):570-573.
• [22]Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA: Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 1991, 83(3):170-178.
• [23]Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998, 79(5):468-475.
• [24]Bausero MA, Bharti A, Page DT, Perez KD, Eng JW, Ordonez SL, Asea EE, Jantschitsch C, Kindas-Muegge I, Ciocca D, et al.: Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell. Tumour Biol 2006, 27(1):17-26.
• [25]Bausero MA, Page DT, Osinaga E, Asea A: Surface expression of Hsp25 and Hsp72 differentially regulates tumor growth and metastasis. Tumour Biol 2004, 25(5-6):243-251.
• [26]Asea A, Ara G, Teicher BA, Stevenson MA, Calderwood SK: Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia 2001, 17(4):347-356.
• [27]Calderwood SK, Asea A: Targeting HSP70-induced thermotolerance for design of thermal sensitizers. Int J Hyperthermia 2002, 18(6):597-608.
• [28]Jaattela M: Programmed cell death: many ways for cells to die decently. Ann Med 2002, 34(6):480-488.
• [29]Farkas B, Hantschel M, Magyarlaki M, Becker B, Scherer K, Landthaler M, Pfister K, Gehrmann M, Gross C, Mackensen A, et al.: Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res 2003, 13(2):147-152.
• [30]Asea A, Kabingu E, Stevenson MA, Calderwood SK: HSP70 peptide-bearing and peptide-negative preparations act as chaperokines. Cell Stress Chaperones 2000, 5(5):425-431.
• [31]Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000, 6(4):435-442.
• [32]Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK: Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002, 277(17):15028-15034.
• [33]Basu S, Suto R, Binder RJ, Srivastava PK: Heat shock proteins as novel mediators of cytokine secretion by macrophages. Cell Stress Chaperones 1998, 3:11-16.
• [34]Hu Y, Smyth GK: ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009, 347(1-2):70-78.
• [35]Asea A, Mallick R, Lechpammer S, Ara G, Teicher BA, Fiorentino S, Stevenson MA, Calderwood SK: Cyclooxygenase inhibitors are potent sensitizers of prostate tumours to hyperthermia and radiation. Int J Hyperthermia 2001, 17(5):401-414.
• [36]Nagaraja GM, Kaur P, Neumann W, Asea EE, Bausero MA, Multhoff G, Asea A: Silencing hsp25/hsp27 Gene Expression Augments Proteasome Activity and Increases CD8+ T-Cell-Mediated Tumor Killing and Memory Responses. Cancer Prev Res (Phila) Dec 20 [Epub ahead of print] 2011.
• [37]Bausero MA, Asea A: Role of Hsp25/27 in metastatic spread of cancer cells. In Heat Shock Proteins in Cancer. Volume 2, edn. Edited by Calderwood SK, Dordrecht Ciocca D. The Netherlands: Springer Publishers; 2007:131-140.
• [38]Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, et al.: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69(4):1302-1313.
• [39]Korkaya H, Paulson A, Iovino F, Wicha MS: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27(47):6120-6130.
• [40]Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et al.: Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010, 102(5):340-351.
• [41]Ciocca DR, Vargas-Roig LM: Hsp27 as a prognostic and predictive factor in cancer. Prog Mol Subcell Biol 2002, 28:205-218.
• [42]Bausero MA, Bharti A, Page DT, Perez KD, Eng JW, Ordonez SL, Asea EE, Jantschitsch C, Kindas-Muegge I, Ciocca D, et al.: Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell. Tumour Biol 2005, 27(1):17-26.
• [43]Bausero MA, Gastpar R, Multhoff G, Asea A: Alternative mechanism by which IFN-gamma enhances tumor recognition: active release of heat shock protein 72. J Immunol 2005, 175(5):2900-2912.
• [44]Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8(3):235-244.
• [45]Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA: Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009, 115(2):423-428.
• [46]Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26(8):1275-1281.
• [47]Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP: Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008, 113(10):2638-2645.
• [48]Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R: Triple-negative breast cancer. Curr Opin Oncol 2008, 20(6):614-620.